Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers

(2017) Monique B. Nilsson et al.   Science Translational Medicine

A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors

(2017) Ji-Youn Han et al.   Cancer Research and Treatment

Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies

(2016) David Planchard et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations

(2016) Hampig Raphael Kourie et al.   Expert Opinion on Drug Metabolism & Toxicology

NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors

(2016) Mengmeng Yang et al.   INTERNATIONAL JOURNAL OF CANCER

Pulse Afatinib for ERBB2 Exon 20 Insertion–Mutated Lung Adenocarcinomas

(2016) Daniel B. Costa et al.   Journal of Thoracic Oncology

Lung cancer patients withHER2mutations treated with chemotherapy andHER2-targeted drugs: results from the European EUHER2 cohort

(2015) J. Mazières et al.   ANNALS OF ONCOLOGY

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

(2015) M. G. Kris et al.   ANNALS OF ONCOLOGY

A systematic analysis of the resistance and sensitivity of HER2YVMAreceptor tyrosine kinase mutant to tyrosine kinase inhibitors in HER2-positive lung cancer

(2015) Xiaokun Shen et al.   JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

(2015) James C-H Yang et al.   LANCET ONCOLOGY

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

(2015) Kenneth S Thress et al.   NATURE MEDICINE

Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer

(2015) Igor F. Tsigelny et al.   Oncotarget

Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignancies

(2014) Yook-Hwan Noh et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Cetuximab Response of Lung Cancer-Derived EGF Receptor Mutants Is Associated with Asymmetric Dimerization

(2013) J. Cho et al.   CANCER RESEARCH

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

Pharmacokinetics of Afatinib, a Selective Irreversible ErbB Family Blocker, in Patients with Advanced Solid Tumours

(2013) Sven Wind et al.   CLINICAL PHARMACOKINETICS

Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

(2013) Julien Mazières et al.   JOURNAL OF CLINICAL ONCOLOGY

Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions

(2013) Geoffrey R. Oxnard et al.   Journal of Thoracic Oncology

Combining Erlotinib and Cetuximab Is Associated with Activity in Patients with Non-Small Cell Lung Cancer (Including Squamous Cell Carcinomas) and Wild-Type EGFR or Resistant Mutations

(2013) J. J. Wheler et al.   MOLECULAR CANCER THERAPEUTICS

EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics

(2013) M. E. Arcila et al.   MOLECULAR CANCER THERAPEUTICS

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

(2013) H. Yasuda et al.   Science Translational Medicine

Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas

(2012) M. E. Arcila et al.   CLINICAL CANCER RESEARCH

Safety, Efficacy and Pharmacokinetics of Neratinib (HKI-272) in Japanese Patients with Advanced Solid Tumors: A Phase 1 Dose-escalation Study

(2012) Y. Ito et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu

(2012) J. De Grève et al.   LUNG CANCER

Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors

(2011) P. A. Janne et al.   CLINICAL CANCER RESEARCH

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications

(2011) Hiroyuki Yasuda et al.   LANCET ONCOLOGY

Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians

(2011) Yongsheng Wang et al.   Therapeutic Advances in Medical Oncology

Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer

(2010) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy

(2009) S. A. Perera et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Erlotinib for Advanced Non–Small-Cell Lung Cancer in the Elderly: An Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21

(2008) Paul Wheatley-Price et al.   JOURNAL OF CLINICAL ONCOLOGY

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations

(2008) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

(2008) D Li et al.   ONCOGENE